ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0266

Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression

RA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0175

Extracorporeal Membrane Oxygenation for Acute Lung Injury in Idiopathic Inflammatory Myopathies – a Potential Lifesaving Intervention

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0084

Facilitators and Barriers of Vaccine Uptake in Patients with Chronic Inflammatory Rheumatic Disease: A Scoping Review

Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

1:00PM-3:00PM: Abstract Number: 0115

Facilitators of Immunosuppressive Medication Adherence in Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers and Clinic Staff

Healthcare Disparities in Rheumatology Poster

1:00PM-3:00PM: Abstract Number: 0373

Factors Associated with Adverse Outcomes in Uveitis Related to Spondylarthritis (SpA-U)- Development of a Prognostic Outcome Score in Patients with SpA-U

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0469

Factors Associated with Corticosteroid Dosing in the Management of Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0382

Factors Associated with Diagnostic Delay in Axial Spondyloarthritis: Impact of Clinical Factors and Social Vulnerability

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0319

Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy

SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

1:00PM-3:00PM: Abstract Number: 0193

Factors Influencing Visit Preference in Patients with Rheumatic Diseases: A Qualitative Study

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0203

Feasibility and Acceptability of Integrating Patient Reported Outcomes Within Routine Care of Rheumatoid Arthritis

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0240

Few and Far Between: Addressing the Pediatric Rheumatology Workforce Gap with a Spotlight on Medicine-pediatrics Residency Trained Rheumatologist Career Paths

Professional Education Poster

1:00PM-3:00PM: Abstract Number: 0030

Fluidic Shear Stress Reduces TNFα-mediated Cartilage Damage in a 3D Model of Degenerative Joint Disease

Osteoarthritis and Joint Biology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0044

Follistatin-like Protein 1 Alters T Cell Receptor Signaling Dynamics in Vitro, While Expression in Vivo Correlates with Disease and Deficiency Increases Acute Inflammation in a Mouse Model of Kawasaki Disease

Pediatric Rheumatology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: PP18

From Devastated to Empowered: How Patient Engagement in Research Changes Lives

Patient Perspectives Poster

1:00PM-3:00PM: Abstract Number: PP05

From Practical Tips to Heartfelt Encouragement: How Social Media Can Improve Quality of Life with Rheumatic Disease

Patient Perspectives Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].